Approximately what percentage of intraocular pressure (IOP) reduction does Timolol provide?

Timolol, a non-selective beta-adrenergic antagonist, is widely used in the treatment of glaucoma to reduce intraocular pressure (IOP). When administered topically as eye drops, it lowers IOP primarily by decreasing the production of aqueous humor, thereby reducing the fluid in the eye that can increase pressure.

Clinical studies have shown that Timolol typically provides an IOP reduction of approximately 25%. This level of efficacy is significant enough to be clinically meaningful in the management of glaucoma, making Timolol a valuable option in therapeutic regimens.

It's important to note that while other medications can provide varying degrees of IOP reduction, the benchmark effect of 25% for Timolol is well established in the literature and is a reason why this particular therapy is often a first-line treatment for patients experiencing elevated IOP.